AIMS: To investigate whether adjuvant antiviral treatment could improve prognosis and @entity17705 is the optimal nucleot(s)ide analogues (NA) regimen after curative therapy of @entity97 -related @entity157 . METHODS: A comprehensive electronic search was performed. All controlled trials comparing antiviral treatment with placebo or no treatment for @entity97 -related @entity157 after curative treatment were included. The pooled hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using Stata 12.0 software. Indirect treatment comparison method was used to compare the relative efficacy of different NA strategies. RESULTS: Twenty-one studies containing 8072 @entity1 were included. NA was found to significantly improve @entity1349 ( @entity1349 ) (HR 0.57, 95% CI 0.43-0.74 in RCTs; HR 0.63, 95% CI 0.54-0.74 in cohort studies) and @entity1349 ( @entity1349 ) (HR 0.41, 95% CI 0.22-0.78 in RCTs; HR 0.62, 95% CI 0.50-0.76 in cohort studies). Alternatively, for interferon, a non-significant benefit was found (HR 0.87, 95% CI 0.70-1.09 for @entity1349 and HR 0.65, 95% CI 0.37-1.15 for @entity1349 in RCTs). By adjusted indirect comparisons among @entity17705 , @entity16332 and @entity24488 , @entity17705 were found to display almost but not significant superiority to the other NA in improving @entity1349 ( @entity16332 versus @entity17705 , HR 2.38, 95%CI 0.91-6.19, P 0.69; @entity24488 versus @entity17705 , HR 2.67, 95%CI 0.99-7.14, P 0.46). No tendency favouring a specific NA regimen was found for @entity1349 . CONCLUSIONS: In @entity97 - @entity157 @entity1 after curative treatment, NA improve the prognosis significantly but the role of interferon remains to be elucidated; @entity17705 was not found to be superior to other NA based on available data. This article is protected by copyright. All rights reserved.

Adjuvant antiviral therapy for @entity97 -related XXXX after curative treatment: A systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity97 :: ('10407', 'Species') :: ['HBV'] @entity16332 :: ('MESH:D019259', 'Chemical') :: ['lamivudine'] @entity24488 :: ('MESH:C053001', 'Chemical') :: ['adefovir'] @entity17705 :: ('MESH:C413685', 'Chemical') :: ['entecavir'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'RFS', 'recurrence-free survival', 'overall survival']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
